These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37701903)

  • 1. Epidemiologic trends and survival of early-onset gastroenteropancreatic neuroendocrine neoplasms.
    Yao H; Hu G; Jiang C; Fan M; Yuan L; Shi H; Lin R
    Front Endocrinol (Lausanne); 2023; 14():1241724. PubMed ID: 37701903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study.
    Poleé IN; Hermans BCM; van der Zwan JM; Bouwense SAW; Dercksen MW; Eskens FALM; Havekes B; Hofland J; Kerkhofs TMA; Klümpen HJ; Latten-Jansen LM; Speel EM; Verburg FA; Walenkamp AME; Geurts SME; de Vos-Geelen J
    Eur J Cancer; 2022 Sep; 172():252-263. PubMed ID: 35803176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland.
    Alwan H; La Rosa S; Andreas Kopp P; Germann S; Maspoli-Conconi M; Sempoux C; Bulliard JL
    Cancer Med; 2020 Dec; 9(24):9454-9461. PubMed ID: 33078908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study.
    Pu N; Habib JR; Bejjani M; Yin H; Nagai M; Chen J; Kinny-Köster B; Chen Q; Zhang J; Yu J; Wu W; Lou W
    Ann Transl Med; 2021 Feb; 9(4):329. PubMed ID: 33708956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
    Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
    J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.
    Zhang XB; Fan YB; Jing R; Getu MA; Chen WY; Zhang W; Dong HX; Dakal TC; Hayat A; Cai HJ; Ashrafizadeh M; Abd El-Aty AM; Hacimuftuoglu A; Liu P; Li TF; Sethi G; Ahn KS; Ertas YN; Chen MJ; Ji JS; Ma L; Gong P
    Mil Med Res; 2024 Jun; 11(1):35. PubMed ID: 38835066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
    Broadbent R; Wheatley R; Stajer S; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E; McNamara MG
    Cancer Treat Rev; 2021 Dec; 101():102299. PubMed ID: 34662810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
    Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
    BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
    Fang JM; Li J; Shi J
    World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
    Shi H; Zhang Q; Han C; Zhen D; Lin R
    BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Mortality Risk among Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Registry-Based Analysis.
    Sun S; Wang W; He C
    Oxid Med Cell Longev; 2021; 2021():9985814. PubMed ID: 34257826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Huang PY; Tsai KL; Liang CM; Tai WC; Rau KM; Wu KL; Huang CC; Chuah SK
    Kaohsiung J Med Sci; 2018 Nov; 34(11):650-656. PubMed ID: 30392572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of CT in differentiating liver metastases of well-differentiated gastroenteropancreatic neuroendocrine neoplasms from poorly-differentiated neuroendocrine neoplasms.
    Cui Y; Li X; Gao S; Li Z; Li Y; Lu M; Sun Y
    Chin J Cancer Res; 2018 Feb; 30(1):31-39. PubMed ID: 29545717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.